MEDIPOST has obtained two international patents related to Alzheimer’s dementia treatment using stem cells.

MEDIPOST has revealed their acquisition of patent rights from the Mexico Patent office concerning ‘pharmacognostical composition for targeted therapy’ that applies the fact that stem cells have tropism functions that explore and detect legions.

This patent concerns the ‘composition for the diagnosis, prevention or treatment of disease related to cells expressing IL-S or GRO-alpha, comprising UCB-MSCs’, which MEDIPOST is to use on ‘NEUROSTEM-AD’, the Alzheimer’s dementia treatment that is in current development.

Additionally, the patented technology can also be used on the detection, diagnosis, and treatment of brain tumors, liver hematoma, colorectal cancer, and malignant b cell neoplasm diseases.

Meanwhile on the 20th, MEDIPOST has also announced the acquisition of a patent related to the ‘composition for the prevention and treatment of nerve diseases’ in Singapore.

This patent has already been registered in Korea, China, Australia, and Mexico, which can widely be used in the treatment of nerve diseases, including Alzheimer’s dementia, Parkinson’s disease, depression, epilepsy, multiple scleroma, and biopolar disease.

The name of the patent is the ‘composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases’.